Новые перспективы в терапии бронхиальной астмы


https://doi.org/10.18093/0869-0189-2011-0-4-5-12

Полный текст:


Об авторе

А. Г. Чучалин
ФГУ "НИИ пульмонологии" ФМБА России
Россия

акад. РАМН, проф., директор 

105077, Москва, ул. 11-я Парковая, 32, корп. 4. Тел.: (495) 465-52-64.



Список литературы

1. Архипов В.В., Цой А.Н., Гавришина Е.В. Клинико-экономическая модель базисной терапии бронхиальной астмы. Клиническая медицина 2007; 2: 63–67.

2. Abbas A.K., Lichtman S.P. Cellular and molecular immunology. 6th ed. Amsterdam: Elsevier; 2010.

3. Lee, S.J., Chinen J., Kavanaugh A. Immunomodulator therapy: monoclonal antibodies, fusion proteins, cytokines and immunoglobulin's. J. Allergy Clin. Immunol. 2010; 125 (Suppl. 2); S314–323.

4. Чучалин А.Г., Раудла Л.А., Татарский А.Р., Лебедин Ю.С. Перспективы развития экстракорпоральной специфической иммуносорбции в лечении больных атопической бронхиальной астмой. Сборник: Тезисы докладов на научно-практической конференции врачей-пульмонологов Сибири и Дальнего Востока "Актуальные вопросы реабилитации больных с патологией органов дыхания". Барнаул; 1989. 46–47.

5. Василов Р.Г. Основные механизмы регуляции синтеза IgE. Новости прикладной иммунологии и аллергологии 1998; 2: 4–5.

6. Shields R.L. et al. Anti-IgE monoclonal antibodies that inhibit allergen-specific histamine release. Int. Arch. Allergy Immunol. 1995; 107: 412–413.

7. Noga O., Hanf G., Kunkel G., Kleine)Tebbe J. Basophil histamine release decreases during omalizumab therapy in allergic asthmatics. Int. Arch. Immunol. 2008; 146 (1): 66–70.

8. Rudolf M.P., Zuercher A.W., Nechansky A. et al. Molecular basis for nonanaphylactogenicity of a monoclonal anti-IgE antibody. J. Immunol. 2000; 165 (2): 813–819.

9. Hayashi N., Tsucamoto Y., Sallas W., Lowe P. A mechanism-based bimding model for the population pharmacokinetics and pharmacodynamics of omalizumab. Brit. J. Clin. Pharmacol. 2006; 63 (5): 548–561.

10. Holgate S.T., Chuchalin A.G. Efficacy a. safety of recombinant anti-immunoglobulin E antibody in severe allergic asthma, 2004.

11. Genentech. XolairR (omalizumab) for subcutaneous use prescribing information. South San Francisco, CA: Genetic Engineering Technology, Inc.; 2008 Jul.

12. Casale T.B., Bernstein I.L., Busse W.W. et al. Use of an antiIgE humanized monoclonal antibody in ragweed-induced allergic rhinitis. J. Allergy Clin. Immunol. 1997; 100: 110–121.

13. Сучкова Ю.Б. Отдаленные результаты применения моноклональных анти-IgE-антител в комплексной терапии тяжелой неконтролируемой атопической бронхиальной астмой: Дис. … канд. мед. наук. М.; 2010.

14. Bousquet J., Cabrera P., Berkman N. et al. The effect of treatment with omalizumab, an anti-IgE antibody, on asthma exacerbation and emergency medical visits in patients with severe persistent asthma. Allergy 2005; 60: 303–308.

15. Limb S.L., Starke P.R., Lee C.E., Chowdhury B.A. Delayed onset and protracted progression of anaphylaxis after omalizumab administration in patients with asthma. J. Allergy Clin. Immunol. 2007; 120: 1378–1381.

16. Сох L.S. How safe are the biologicals in treating asthma and rhinitis? Allergy, asthma, clin. Immunol. 2009; 5 (1): 4.

17. Singh J., Kraft M. Anti-IgE and other antibody targets in asthma. Handb. Exp. Pharmacol. 2008; 181: 257–288.

18. Leckie M.J., Brinke A., Diamant Z. et al. Effects of interleukin-5 blocking monoclonal antibody on eosinophils, airway hyper-responsiveness and the late asthmatic response. Lancet 2000, 356: 2144–2148.

19. Flood)Page P., Swenson C., Faiferman I. et al. A study of evaluate safety and efficacy of mepolizumab in patients with moderate persistent asthma. Am. J. Resp. Crit. Care Med. 2007; 176: 1062–1071.

20. Kips J.C., O`Conner B.J., Langley S.J. et al. Effect of SCH55700, a humanized anti-human interleukin-5 antibody, in severe persistent asthma: a pilot study. Am. J. Respir. Crit. Care Med. 2003; 167: 1655–1559.

21. Haldar P., Brightling C.E., Hargadon B. et al. Mepolizumab and exacerbations of refractory eosinophilic asthma N. Engl. J. Med. 2009; 360: 973–984.

22. Koike M., Nakamura K., Furuya A. et al. Establishment of humanized anti-interleukin-5 receptor alpha chain monoclonal antibodies having a potent neutralizing activity. Hum. Antibodies 2009; 18: 17–27.

23. Busse W.W., Katial R., Gossage D. et al. Safety profile, pharmacokinetics and biological activity MEDI-563, anti-IL-5 receptor alpha antibody, in phase 1 study of subjects with mild asthma. J. Allergy Clin. Immunol. 2010; 125: 1237–1244.

24. Gruenberg D., Busse W.W. Biological therapies for asthma. Curr. Opin. Pulm. Med. 2010; 16: 19–24.

25. Erin E.M., Leaker B.R., Nicholson G.C. et al. The effects of a monoclonal antibody directed against tumor necrosis factor-alpha in asthma. Am. J. Respir. Crit. Care Med. 2006; 174: 753–762.

26. Wenzel S.E., Barnes P.J., Bleecker E.R. et al. A randomized, double-blind, placebo-controlled study of tumor necrosis factor-alpha blocked in severe persistent asthma. Am. J. Respir. Crit. Care Med. 2009; 179: 549–558.

27. Lee S.J., Chinen J., Kavanaugh A. Immunomodulator therapy: monoclonal antibodies, fusion proteins, cytokines and immunoglobulins. J. Allergy Clin. Immunol. 2010; 125 (Suppl. 2): S314–323.

28. Howarth P.H., Babu K.S., Arshad H.S. et al. Tumor necrosis factor (TNF-alpha) as a novel therapeutic target in symptomatic corticosteroid dependet asthma. Thorax 2005; 60: 1012–1018.

29. Doherty T., Broide D. Cytokines and growth factors in airway remodeling in asthma. Curr. Opin. Immunol. 2007; 19: 676–680.

30. Busse W.W., Israel E., Nelson H.S. et al. Daclizumab improves asthma control in patients with moderate to severe persistent asthma: a randomized controlled trial. Am. J. Respir. Crit. Care Med. 2008; 178: 1002–1008.

31. Hart T.K., Blackburn M.N., Brigham)Burke M. et al. Preclinical efficacy and safty of pascolizumab: a humanized antiinterleukin-4 antibody with therapeutic potential in asthma. Clin. Exp. Immunol. 2002; 130: 93–100.

32. Long A.A. Monoclonal antibodies and other biological agents in treatment of asthma. MAbs 2009; 1: 237–246.

33. Poole J.A., Meng J., Reff M. et al. Anti-CD23 monoclonal antibody, lumiliximab, inhibited allergen-induced responses in antigen-presenting cells and T cells from atopic subjects. J. Allergy Clin. Immunol. 2005; 116: 780–788.

34. Kon O.M., Sihra B.S., Compton C.H. et al. Randomized dose-ranging placebo-controlled study of chemeric antibody to CD4 (keliximab) in chronic severe asthma. Lancet 1998; 352: 1109–1113.

35. Corren J., Busse W., Meltzer E.O. et al. A randomized controlled phase 11 study of AMG317, an IL-4R-alpha antagonist in patients with asthma. Am. J. Respir. Crit. Care Med. 2010; 181: 788–796.


Дополнительные файлы

Для цитирования: Чучалин А.Г. Новые перспективы в терапии бронхиальной астмы.  Пульмонология. 2011;(4):5-12. https://doi.org/10.18093/0869-0189-2011-0-4-5-12

For citation: Chuchalin A.G. Bronchial asthma: novel therapeutic approaches. Russian Pulmonology. 2011;(4):5-12. (In Russ.) https://doi.org/10.18093/0869-0189-2011-0-4-5-12

Просмотров: 621

Обратные ссылки

  • Обратные ссылки не определены.


ISSN 0869-0189 (Print)
ISSN 2541-9617 (Online)